Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Lee, Byung-Hyun | - |
dc.contributor.author | Jeon, Min Ji | - |
dc.contributor.author | Yu, Eun Sang | - |
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.date.accessioned | 2021-08-30T12:24:36Z | - |
dc.date.available | 2021-08-30T12:24:36Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2040-6207 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/52555 | - |
dc.description.abstract | Background: Although many acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients have been treated with hypomethylating agents (HMAs) as a substitute for intensive chemotherapy in recent years, the incidence of invasive fungal infections (IFIs) and the efficacy of posaconazole as antifungal prophylaxis in these patients are not well known to date. Methods: We retrospectively analyzed 280 AML and MDS patients treated with HMAs to identify IFI incidence and posaconazole efficacy as antifungal prophylaxis in these patients. Results: The overall incidence of probable or proven IFIs was 7.9% (22/280 patients): 11.5% in the no-use group (17/148 patients) and 3.8% in the posaconazole group (5/132 patients). Most IFIs occurred during the early cycles of the HMAs (median: 3 cycles; range: 1-8 cycles), especially in patients who had neutropenia or did not respond to HMAs. Posaconazole significantly lowered IFI incidence compared with that in the no-use group in univariate and multivariate analyses. Moreover, patients who had reduced liver function at HMA initiation, were treated with decitabine therapy, and did not respond to HMA chemotherapy were independently associated with a higher IFI risk. In subgroup analysis, posaconazole appeared to be more beneficial for patients with good Eastern Cooperative Oncology Group performance score or liver function at HMA initiation. Conclusion: Thus, in AML and MDS patients receiving HMAs, IFI risk may be high during the early cycles, especially when the underlying disease is not controlled. Posaconazole could represent antifungal prophylaxis in these patients; further studies are needed for its appropriate indications. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject | INTERNATIONAL WORKING GROUP | - |
dc.subject | INVASIVE FUNGAL-INFECTIONS | - |
dc.subject | EUROPEAN ORGANIZATION | - |
dc.subject | RESPONSE CRITERIA | - |
dc.subject | CLINICAL-PRACTICE | - |
dc.subject | AZACITIDINE | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | DIAGNOSIS | - |
dc.subject | DISEASE | - |
dc.subject | RECOMMENDATIONS | - |
dc.title | Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dae Sik | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1177/2040620720966882 | - |
dc.identifier.wosid | 000585129400001 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN HEMATOLOGY, v.11 | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN HEMATOLOGY | - |
dc.citation.title | THERAPEUTIC ADVANCES IN HEMATOLOGY | - |
dc.citation.volume | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | INTERNATIONAL WORKING GROUP | - |
dc.subject.keywordPlus | INVASIVE FUNGAL-INFECTIONS | - |
dc.subject.keywordPlus | EUROPEAN ORGANIZATION | - |
dc.subject.keywordPlus | RESPONSE CRITERIA | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE | - |
dc.subject.keywordPlus | AZACITIDINE | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordAuthor | antifungal prophylaxis | - |
dc.subject.keywordAuthor | hypomethylating agent | - |
dc.subject.keywordAuthor | invasive fungal infection | - |
dc.subject.keywordAuthor | posaconazole | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.